: Despite a "chaotic news cycle," markets remained remarkably steady, allowing growth premiums to outperform value premiums significantly.

: This biotechnology firm was a standout, posting a 426% return in 2017. Its growth was driven by positive clinical trial results for its cholesterol-reducing drug candidate.

For investors in 2017, the "high-risk, high-reward" segment of the market was defined by a strong rebound in energy, explosive breakthroughs in biotechnology, and the rising dominance of high-growth technology. While the broader market saw a lack of volatility, with the S&P 500 rising roughly 20% and the Nasdaq nearly 30%, these specific sectors offered triple-digit gains for those willing to stomach higher volatility.